Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 9/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10671160 | 0.99 | PSMB8 (0.55) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4138516 | 0.88 | PSMB5 (0.53) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL10671152 | 0.87 | PSMB5 (0.52) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL3142808 | 0.87 | PSMB5 (0.52) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL7956758 | 0.87 | PSMB5 (0.55) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL21836357 | 0.86 | PSMB5 (0.54) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL21836382 | 0.85 | PSMB5 (0.50) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6839194 | 0.83 | PSMB5 (0.49) | PSMB8PSMB5SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL10664751 | 0.83 | PSMB8 (0.62) | PSMB8PSMB5MEN1ALDH1A1HPGD | |
| SCHEMBL806348 | 0.83 | ALDH1A1 (0.54) | PSMB8PSMB5MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3852751-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-112955142-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
| WO-2020061435-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-4751306-A | Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuroisoquinolines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PSMB8 1331/4885PSMB5 293/4885SMN1; SMN2 4669/4885 |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PSMB8 1331/4885PSMB5 293/4885SMN1; SMN2 4669/4885 |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PSMB8 1331/4885PSMB5 293/4885SMN1; SMN2 4669/4885 |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PSMB8 1331/4885PSMB5 293/4885SMN1; SMN2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.